Heron Therapeutics (NASDAQ:HRTX) Upgraded to “Buy” by BidaskClub

Heron Therapeutics (NASDAQ:HRTX) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Saturday, January 20th.

Several other equities research analysts have also recently weighed in on HRTX. Mizuho started coverage on Heron Therapeutics in a research note on Tuesday, September 26th. They set a “buy” rating and a $28.00 target price for the company. Northland Securities started coverage on Heron Therapeutics in a research note on Wednesday, September 27th. They issued an “outperform” rating and a $40.00 price target for the company. Noble Financial reiterated a “buy” rating and issued a $24.00 price target on shares of Heron Therapeutics in a research note on Friday, October 6th. Zacks Investment Research upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. Finally, Oppenheimer restated a “buy” rating and issued a $27.00 price objective on shares of Heron Therapeutics in a report on Friday, November 10th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $28.82.

Shares of Heron Therapeutics (NASDAQ:HRTX) traded up $0.80 during mid-day trading on Friday, hitting $23.20. The company had a trading volume of 818,196 shares, compared to its average volume of 1,012,261. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62. Heron Therapeutics has a fifty-two week low of $12.70 and a fifty-two week high of $24.80. The company has a market capitalization of $1,230.00, a PE ratio of -6.12 and a beta of 1.87.

In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total transaction of $151,680.00. Following the completion of the sale, the vice president now directly owns 7,584 shares in the company, valued at approximately $151,680. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 19.93% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Parametric Portfolio Associates LLC grew its stake in shares of Heron Therapeutics by 2.3% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 771 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Heron Therapeutics by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock valued at $2,363,000 after buying an additional 1,026 shares during the period. HighTower Advisors LLC grew its stake in shares of Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 1,700 shares during the period. Tudor Investment Corp ET AL grew its stake in shares of Heron Therapeutics by 10.2% in the 2nd quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock valued at $258,000 after buying an additional 1,724 shares during the period. Finally, Legal & General Group Plc grew its stake in shares of Heron Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 2,383 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Heron Therapeutics (NASDAQ:HRTX) Upgraded to “Buy” by BidaskClub” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/14/heron-therapeutics-hrtx-raised-to-buy-at-bidaskclub.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply